zepbound tirzepatide eli lilly Lilly's weight loss, diabetes drug tops Keytruda as world's best-selling medicine Eli Lilly says weight-loss drug

GIP, like GLP-1, is an incretin hormone secreted by intestinal K cells in response to nutrient intake

Standard clinical practice is to administer the first tirzepatide dose (2.5 mg) on the same injection day the semaglutide dose would have been due, then escalate tirzepatide at the label-specified 4-week intervals regardless of what semaglutide dose the patient was on

Understanding how they work is crucial when considering their potential risks and benefits for pregnancy

If the body is introduced to high levels of a GLP-1 or GIP agonist too quickly, the digestive system may react strongly, leading to significant discomfort

Tirzepatide has demonstrated promising results in clinical trials, demonstrating significant improvements in glycemic control and potential for weight loss in both diabetic and nondiabetic adults

These findings underscore the drugs potential to transform treatment for obesity-related conditions and improve overall health outcomes.